Invokana Claim

Invokana (canagliflozin) and Invokanamet are diabetes drugs that work by helping the kidneys rid the bloodstream of glucose. Unlike traditional diabetes drugs that target the pancreas and liver, Invokana and Invokanamet target the kidneys to stop the body from reabsorbing sugar.

On May 15, 2015, the FDA issued a Safety Announcement based on increasing reports of Diabetic Ketoacidosis in users of Invokana and Invokanamet. Later the same year, an FDA safety review resulted in the addition of Diabetic Ketoacidosis warnings in both drugs’ labels.

On June 14, 2016, the FDA strengthened its warning about the risk of kidney injury for drug Invokana and Invokanamet, to include information about the risk of acute kidney injury.

Side effects include:

Diabetic Ketoacidosis

Acute Kidney Injury

Kidney Failure

Heart Attack

Diabetic Ketoacidosis is a very serious condition that causes high levels of blood acids, or ketones, which are poisonous. This condition typically occurs when the body loses its ability to produce sufficient insulin. Acute Kidney Injury is similarly serious, in which the kidneys begin to stop functioning, causing a dangerous rise in the levels of waste in the body.